{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Rifapentine",
    "query": {
      "intervention": "Rifapentine"
    },
    "page_size": 10
  },
  "pagination": {
    "page": 1,
    "page_size": 10,
    "total_count": 27,
    "total_pages": 3,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Rifapentine&page=2&page_size=10",
    "previous_page_url": null
  },
  "source": "remote",
  "last_synced_at": "2026-09-10T08:48:40.133Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT01690403",
      "title": "Interaction Study to Assess the Pharmacokinetic Interaction of Oral Administration of Rifapentine on ATRIPLA™ in HIV Patients",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Tuberculosis"
      ],
      "interventions": [
        {
          "name": "rifapentine (M000473)",
          "type": "DRUG"
        },
        {
          "name": "EFZ EMT TDF",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Sanofi",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "55 Years",
        "sex": "ALL",
        "summary": "18 Years to 55 Years"
      },
      "enrollment_count": 25,
      "start_date": "2012-12",
      "completion_date": "2014-03",
      "has_results": false,
      "last_update_posted_date": "2015-02-27",
      "last_synced_at": "2026-09-10T08:48:40.133Z",
      "location_count": 1,
      "location_summary": "Buffalo, New York",
      "locations": [
        {
          "city": "Buffalo",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01690403"
    },
    {
      "nct_id": "NCT01574638",
      "title": "Evaluating the Pharmacokinetics of High-Dose Rifapentine When Given as a Single Dose or in Divided Doses to Healthy Adults",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Tuberculosis"
      ],
      "interventions": [
        {
          "name": "Rifapentine (RPT)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "National Institute of Allergy and Infectious Diseases (NIAID)",
      "sponsor_class": "NIH",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "18 Years to 65 Years"
      },
      "enrollment_count": 44,
      "start_date": "2012-06",
      "completion_date": "2013-06",
      "has_results": false,
      "last_update_posted_date": "2021-11-05",
      "last_synced_at": "2026-09-10T08:48:40.133Z",
      "location_count": 4,
      "location_summary": "San Diego, California • Baltimore, Maryland • Chapel Hill, North Carolina + 1 more",
      "locations": [
        {
          "city": "San Diego",
          "state": "California"
        },
        {
          "city": "Baltimore",
          "state": "Maryland"
        },
        {
          "city": "Chapel Hill",
          "state": "North Carolina"
        },
        {
          "city": "Nashville",
          "state": "Tennessee"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01574638"
    },
    {
      "nct_id": "NCT03783728",
      "title": "Video Based Directly Observed Therapy for Latent TB",
      "overall_status": "WITHDRAWN",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Latent Tuberculosis"
      ],
      "interventions": [
        {
          "name": "Rifapentine 600 mg orally",
          "type": "DRUG"
        },
        {
          "name": "Isoniazid 900 mg orally",
          "type": "DRUG"
        },
        {
          "name": "Pyridoxine 50 mg orally",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "St. Louis University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "80 Years",
        "sex": "ALL",
        "summary": "18 Years to 80 Years"
      },
      "enrollment_count": 0,
      "start_date": "2019-06-30",
      "completion_date": "2020-01-31",
      "has_results": false,
      "last_update_posted_date": "2019-07-01",
      "last_synced_at": "2026-09-10T08:48:40.133Z",
      "location_count": 1,
      "location_summary": "St Louis, Missouri",
      "locations": [
        {
          "city": "St Louis",
          "state": "Missouri"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03783728"
    },
    {
      "nct_id": "NCT03474029",
      "title": "Assessment of the Safety, Tolerability, and Effectiveness of Rifapentine Given Daily for LTBI",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2",
        "PHASE3"
      ],
      "conditions": [
        "Latent Tuberculosis"
      ],
      "interventions": [
        {
          "name": "Rifapentine daily for 6 weeks",
          "type": "DRUG"
        },
        {
          "name": "Rifapentine and Isoniazid weekly for 12 weeks",
          "type": "DRUG"
        },
        {
          "name": "Rifampin and Isoniazid daily for 12 weeks",
          "type": "DRUG"
        },
        {
          "name": "Rifampin daily for 16 weeks",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Centers for Disease Control and Prevention",
      "sponsor_class": "FED",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": null,
        "sex": "ALL",
        "summary": "Not listed"
      },
      "enrollment_count": 3400,
      "start_date": "2019-08-01",
      "completion_date": "2029-12-31",
      "has_results": false,
      "last_update_posted_date": "2026-05-06",
      "last_synced_at": "2026-09-10T08:48:40.133Z",
      "location_count": 7,
      "location_summary": "Denver, Colorado • Washington D.C., District of Columbia • Manhattan, New York + 3 more",
      "locations": [
        {
          "city": "Denver",
          "state": "Colorado"
        },
        {
          "city": "Washington D.C.",
          "state": "District of Columbia"
        },
        {
          "city": "Washington D.C.",
          "state": "District of Columbia"
        },
        {
          "city": "Manhattan",
          "state": "New York"
        },
        {
          "city": "New York",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03474029"
    },
    {
      "nct_id": "NCT03886701",
      "title": "Doravirine, Rifapentine and Isoniazid Interaction",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Latent Tuberculosis",
        "Human Immunodeficiency Virus",
        "Rifamycins Causing Adverse Effects in Therapeutic Use",
        "Drug Interaction Potentiation"
      ],
      "interventions": [
        {
          "name": "Doravirine (DOR)",
          "type": "DRUG"
        },
        {
          "name": "Rifapentine (RPT)",
          "type": "DRUG"
        },
        {
          "name": "Isoniazid (INH)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Walter K. Kraft",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "60 Years",
        "sex": "ALL",
        "summary": "18 Years to 60 Years"
      },
      "enrollment_count": 11,
      "start_date": "2019-04-22",
      "completion_date": "2019-05-20",
      "has_results": true,
      "last_update_posted_date": "2020-03-27",
      "last_synced_at": "2026-09-10T08:48:40.133Z",
      "location_count": 1,
      "location_summary": "Philadelphia, Pennsylvania",
      "locations": [
        {
          "city": "Philadelphia",
          "state": "Pennsylvania"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03886701"
    },
    {
      "nct_id": "NCT00460759",
      "title": "Pharmacokinetic Issues of Moxifloxacin Plus Rifapentine",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Mycobacterium Tuberculosis"
      ],
      "interventions": [
        {
          "name": "Moxifloxacin",
          "type": "DRUG"
        },
        {
          "name": "Rifapentine",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Johns Hopkins University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "18 Years to 65 Years"
      },
      "enrollment_count": 15,
      "start_date": "2007-06",
      "completion_date": "2008-08-24",
      "has_results": false,
      "last_update_posted_date": "2017-12-07",
      "last_synced_at": "2026-09-10T08:48:40.133Z",
      "location_count": 1,
      "location_summary": "Baltimore, Maryland",
      "locations": [
        {
          "city": "Baltimore",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00460759"
    },
    {
      "nct_id": "NCT00164450",
      "title": "TBTC Study 26 PK: Rifapentine Pharmacokinetics in Children During Treatment of Latent TB Infection",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Tuberculosis"
      ],
      "interventions": [
        {
          "name": "Isoniazid",
          "type": "DRUG"
        },
        {
          "name": "Rifapentine",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Centers for Disease Control and Prevention",
      "sponsor_class": "FED",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "2 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "2 Years and older"
      },
      "enrollment_count": 158,
      "start_date": "2005-09",
      "completion_date": "2008-08",
      "has_results": true,
      "last_update_posted_date": "2026-07-07",
      "last_synced_at": "2026-09-10T08:48:40.133Z",
      "location_count": 19,
      "location_summary": "Little Rock, Arkansas • Los Angeles, California • San Diego, California + 16 more",
      "locations": [
        {
          "city": "Little Rock",
          "state": "Arkansas"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "San Diego",
          "state": "California"
        },
        {
          "city": "San Francisco",
          "state": "California"
        },
        {
          "city": "Denver",
          "state": "Colorado"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00164450"
    },
    {
      "nct_id": "NCT02563327",
      "title": "Pharmacokinetic and Pharmacodynamic Study of High-Dose Rifapentine and Moxifloxacin for Treatment of Tuberculosis",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Tuberculosis"
      ],
      "interventions": [
        {
          "name": "Rifapentine",
          "type": "DRUG"
        },
        {
          "name": "Moxifloxacin",
          "type": "DRUG"
        },
        {
          "name": "Rifampin",
          "type": "DRUG"
        },
        {
          "name": "Isoniazid",
          "type": "DRUG"
        },
        {
          "name": "Pyrazinamide",
          "type": "DRUG"
        },
        {
          "name": "Ethambutol",
          "type": "DRUG"
        },
        {
          "name": "Pyridoxine",
          "type": "DIETARY_SUPPLEMENT"
        }
      ],
      "intervention_types": [
        "DRUG",
        "DIETARY_SUPPLEMENT"
      ],
      "sponsor": "Centers for Disease Control and Prevention",
      "sponsor_class": "FED",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 2516,
      "start_date": "2016-01-25",
      "completion_date": "2021-08-30",
      "has_results": true,
      "last_update_posted_date": "2026-08-27",
      "last_synced_at": "2026-09-10T08:48:40.133Z",
      "location_count": 1,
      "location_summary": "San Antonio, Texas",
      "locations": [
        {
          "city": "San Antonio",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02563327"
    },
    {
      "nct_id": "NCT02216331",
      "title": "PK Interaction Between Rifapentine or Rifampicin and a Single Dose of TMC207 in Healthy Subjects (TMC207-CL002)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Tuberculosis"
      ],
      "interventions": [
        {
          "name": "TMC207",
          "type": "DRUG"
        },
        {
          "name": "rifapentine",
          "type": "DRUG"
        },
        {
          "name": "rifampicin",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Global Alliance for TB Drug Development",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "19 Years",
        "maximum_age": "55 Years",
        "sex": "ALL",
        "summary": "19 Years to 55 Years"
      },
      "enrollment_count": 32,
      "start_date": "2010-03",
      "completion_date": "2010-05",
      "has_results": false,
      "last_update_posted_date": "2019-09-06",
      "last_synced_at": "2026-09-10T08:48:40.133Z",
      "location_count": 1,
      "location_summary": "Lincoln, Nebraska",
      "locations": [
        {
          "city": "Lincoln",
          "state": "Nebraska"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02216331"
    },
    {
      "nct_id": "NCT02641106",
      "title": "VDOT for Monitoring Adherence to LTBI Treatment",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Tuberculosis",
        "Latent Tuberculosis Infection"
      ],
      "interventions": [
        {
          "name": "Video Directly Observed Therapy",
          "type": "OTHER"
        },
        {
          "name": "In-Person DOT",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "OTHER"
      ],
      "sponsor": "University of California, San Diego",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "13 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "13 Years and older"
      },
      "enrollment_count": 129,
      "start_date": "2016-03-08",
      "completion_date": "2020-06-30",
      "has_results": false,
      "last_update_posted_date": "2021-02-05",
      "last_synced_at": "2026-09-10T08:48:40.133Z",
      "location_count": 1,
      "location_summary": "San Diego, California",
      "locations": [
        {
          "city": "San Diego",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02641106"
    }
  ]
}